{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:58:25Z","timestamp":1790791105381,"version":"4.1.0"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":251,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite encouraging advances in cancer immunotherapy, several malignancies leverage resistance pathways to escape the effects of treatment. Abnormal cell signaling and cytokine secretion modulated by cancer cells promote a tumor microenvironment (TME), wherein the efficacy of infiltrating immune cells is diminished. There is increasing evidence that alteration of the glycosylation profile of some TMEs is a key factor in exhausting the immune response. The sialic-acid\/Siglec axis has received attention for its suspected involvement in this context through both preclinical study and several clinical trials. Against this backdrop, glioblastoma (GBM) is a well-established immune-suppressive tumor with disappointing responses to most traditional immunotherapies. Recent studies have suggested that GBM can exploit the sialic-acid\/Siglec axis to promote immune evasion and resistance to traditional immune checkpoint inhibitors. This review examines all presently identified Siglec interactions and the current state of Siglec-centered therapies with respect to GBM.<\/jats:p>","DOI":"10.1093\/noajnl\/vdag234","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:52:57Z","timestamp":1788616377000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Siglec\/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms"],"prefix":"10.1093","volume":"8","author":[{"given":"David","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"ElNemer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Selim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"},{"name":"Baroda Medical College, Maharaja Sayajirao University of Baroda , Baroda,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"},{"name":"University of Maryland , College Park, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Slika","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Ruchika","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Brem","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty M","family":"Tyler","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University, School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026093013304848100_vdag234-B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026093013304848100_vdag234-B2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026093013304848100_vdag234-B3","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed \u00adglioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026093013304848100_vdag234-B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026093013304848100_vdag234-B5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026093013304848100_vdag234-B6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-023-00491-8","article-title":"Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy","volume":"11","author":"Yue","year":"2023","journal-title":"Biomark Res"},{"key":"2026093013304848100_vdag234-B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/acschemneuro.7b00271","article-title":"Glycosylation changes in brain cancer","volume":"9","author":"Veillon","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"2026093013304848100_vdag234-B8","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1038\/s41598-024-51973-0","article-title":"Predictive potentials of glycosylation-related genes in glioma prognosis and their correlation with immune infiltration","volume":"14","author":"Sun","year":"2024","journal-title":"Sci Rep"},{"key":"2026093013304848100_vdag234-B9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/path.6401","article-title":"Distinct spatial N-glycan profiles reveal glioblastoma-specific signatures","volume":"265","author":"Angerstein","year":"2025","journal-title":"J Pathol"},{"key":"2026093013304848100_vdag234-B10","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.18632\/oncotarget.27850","article-title":"Terminally sialylated and fucosylated complex N-glycans are involved in the malignant behavior of high-grade glioma","volume":"11","author":"Cuello","year":"2020","journal-title":"Oncotarget"},{"key":"2026093013304848100_vdag234-B11","doi-asserted-by":"publisher","first-page":"11645","DOI":"10.3390\/ijms241411645","article-title":"Deciphering the action of neuraminidase in glioblastoma models","volume":"24","author":"Baeza-Kallee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026093013304848100_vdag234-B12","doi-asserted-by":"publisher","first-page":"e158799","DOI":"10.1172\/jci.insight.158799","article-title":"\u03b12,6 sialylation mediated by ST6GAL1 promotes glioblastoma growth","volume":"7","author":"Gc","year":"2022","journal-title":"JCI Insight"},{"key":"2026093013304848100_vdag234-B13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/neuonc\/noad101","article-title":"Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma","volume":"25","author":"Kuliesiute","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026093013304848100_vdag234-B14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2026093013304848100_vdag234-B15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the Siglec\u2013sialic acid immune axis in cancer: current and future approaches","volume":"10","author":"L\u00e4ubli","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026093013304848100_vdag234-B16","doi-asserted-by":"publisher","first-page":"1411072","DOI":"10.3389\/fimmu.2024.1411072","article-title":"High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients","volume":"15","author":"An","year":"2024","journal-title":"Front Immunol"},{"key":"2026093013304848100_vdag234-B17","doi-asserted-by":"publisher","first-page":"1065062","DOI":"10.3389\/fimmu.2023.1065062","article-title":"Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2026093013304848100_vdag234-B18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"key":"2026093013304848100_vdag234-B19","doi-asserted-by":"publisher","first-page":"112949","DOI":"10.1016\/j.yexcr.2021.112949","article-title":"Targeting alpha2,3-sialylated glycan in glioma stem-like cells by Maackia amurensis lectin-II: a promising strategy for glioma treatment","volume":"410","author":"Putthisen","year":"2022","journal-title":"Exp Cell Res"},{"key":"2026093013304848100_vdag234-B20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/glycob\/cwi071","article-title":"Polysialic acid facilitates tumor invasion by glioma cells","volume":"15","author":"Suzuki","year":"2005","journal-title":"Glycobiology"},{"key":"2026093013304848100_vdag234-B21","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/cells12232758","article-title":"Glycation interferes with the expression of sialyltransferases and leads to increased polysialylation in glioblastoma cells","volume":"12","author":"Schildhauer","year":"2023","journal-title":"Cells"},{"key":"2026093013304848100_vdag234-B22","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1074\/jbc.274.17.11505","article-title":"The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2","volume":"274","author":"Taylor","year":"1999","journal-title":"J Biol Chem"},{"key":"2026093013304848100_vdag234-B23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V96.2.483.014k40_483_490","article-title":"Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2","volume":"96","author":"Paul","year":"2000","journal-title":"Blood"},{"key":"2026093013304848100_vdag234-B24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/1750743X.2025.2493038","article-title":"CD33-D2 isoform characterization for advancement of its therapeutic potential","volume":"17","author":"Shastri","year":"2025","journal-title":"Immunotherapy"},{"key":"2026093013304848100_vdag234-B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-021-09116-5","article-title":"Targeting CD33 for acute myeloid leukemia therapy","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"key":"2026093013304848100_vdag234-B26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00262-019-02302-2","article-title":"Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates","volume":"68","author":"Cassetta","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2026093013304848100_vdag234-B27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.intimp.2015.10.014","article-title":"Correlation between myeloid-derived suppressor cells and S100A8\/A9 in tumor and autoimmune diseases","volume":"29","author":"Zheng","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"2026093013304848100_vdag234-B28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed \u00adglioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro Oncol"},{"key":"2026093013304848100_vdag234-B29","doi-asserted-by":"publisher","first-page":"e122264","DOI":"10.1172\/jci.insight.122264","article-title":"Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis","volume":"3","author":"Alban","year":"2018","journal-title":"JCI Insight"},{"key":"2026093013304848100_vdag234-B30","doi-asserted-by":"publisher","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"key":"2026093013304848100_vdag234-B31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/imm.13470","article-title":"Siglec-5 is an inhibitory immune checkpoint molecule for human T cells","volume":"166","author":"Vuchkovska","year":"2022","journal-title":"Immunology"},{"key":"2026093013304848100_vdag234-B32","doi-asserted-by":"publisher","first-page":"104841","DOI":"10.1016\/j.ebiom.2023.104841","article-title":"The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis","volume":"97","author":"Lozano-Rodr\u00edguez","year":"2023","journal-title":"EBioMedicine"},{"key":"2026093013304848100_vdag234-B33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00262-019-02332-w","article-title":"Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma","volume":"68","author":"Santegoets","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2026093013304848100_vdag234-B34","doi-asserted-by":"publisher","first-page":"e180282","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J Clin Invest"},{"key":"2026093013304848100_vdag234-B35","doi-asserted-by":"publisher","first-page":"43117","DOI":"10.1074\/jbc.M403538200","article-title":"Negative regulation of T cell receptor signaling by Siglec-7 (p70\/AIRM) and Siglec-9","volume":"279","author":"Ikehara","year":"2004","journal-title":"J Biol Chem"},{"key":"2026093013304848100_vdag234-B36","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"2026093013304848100_vdag234-B37","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.2147\/OTT.S223406","article-title":"Siglecs, novel immunotherapy targets, potentially enhance the effectiveness of existing immune checkpoint inhibitors in glioma immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2026093013304848100_vdag234-B38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/bj3550489","article-title":"Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor","volume":"355","author":"Munday","year":"2001","journal-title":"Biochem J"},{"key":"2026093013304848100_vdag234-B39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage siglec-10 is a new target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"2026093013304848100_vdag234-B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat Neurosci"},{"key":"2026093013304848100_vdag234-B41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2026093013304848100_vdag234-B42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cmi.2009.119","article-title":"CD24: from A to Z","volume":"7","author":"Fang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"2026093013304848100_vdag234-B43","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1073\/pnas.1722056115","article-title":"CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function","volume":"115","author":"Bandala-Sanchez","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026093013304848100_vdag234-B44","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3389\/fimmu.2019.01967","article-title":"Specific sialoforms required for the immune suppressive activity of human soluble CD52","volume":"10","author":"Shathili","year":"2019","journal-title":"Front Immunol"},{"key":"2026093013304848100_vdag234-B45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat Immunol"},{"key":"2026093013304848100_vdag234-B46","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.2147\/CMAR.S210545","article-title":"LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression","volume":"11","author":"Chai","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026093013304848100_vdag234-B47","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.xcrm.2023.101380","article-title":"Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors","volume":"5","author":"Pettinella","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026093013304848100_vdag234-B48","doi-asserted-by":"publisher","first-page":"873655","DOI":"10.3389\/fgene.2022.873655","article-title":"Siglec10\u2014an immunosuppressor and negative predictor of survival prognosis in gliomas","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"key":"2026093013304848100_vdag234-B49","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1007\/s00432-021-03762-9","article-title":"Regulation of prognosis-related Siglecs in the glioma microenvironment","volume":"147","author":"Mao","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026093013304848100_vdag234-B50","author":"OncoC4, Inc","year":"2024"},{"key":"2026093013304848100_vdag234-B51","doi-asserted-by":"publisher","first-page":"e2300366120","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026093013304848100_vdag234-B52","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.06.652455","article-title":"Targeting siglec-10\/\u03b13\u03b21 integrin interactions enhances macrophage-mediated phagocytosis of pancreatic cancer","author":"Saini","year":"2025","journal-title":"bioRxiv"},{"key":"2026093013304848100_vdag234-B53","doi-asserted-by":"publisher","first-page":"e2502758","DOI":"10.1002\/adma.202502758","article-title":"Signal transducer nanoparticles enable Siglec-10\/G blockade immunotherapy for breast cancer treatment","volume":"37","author":"Meng","year":"2025","journal-title":"Adv Mater"},{"key":"2026093013304848100_vdag234-B54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/abt\/tbad020","article-title":"IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24\/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy","volume":"6","author":"Li","year":"2023","journal-title":"Antib Ther"},{"key":"2026093013304848100_vdag234-B55","doi-asserted-by":"publisher","first-page":"2300288","DOI":"10.1002\/advs.202300288","article-title":"Nano-LYTACs for degradation of membrane proteins and inhibition of CD24\/Siglec-10 signaling pathway","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci"},{"key":"2026093013304848100_vdag234-B56","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.omto.2023.100747","article-title":"Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy","volume":"31","author":"Yang","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"2026093013304848100_vdag234-B57","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1111\/jcmm.17868","article-title":"Effects of blocking CD24 and CD47 \u2018don\u2019t eat me\u2019 signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia","volume":"27","author":"Aroldi","year":"2023","journal-title":"J Cell Mol Med"},{"key":"2026093013304848100_vdag234-B58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026093013304848100_vdag234-B59","doi-asserted-by":"publisher","first-page":"1159085","DOI":"10.3389\/fimmu.2023.1159085","article-title":"Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"2026093013304848100_vdag234-B60","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"2026093013304848100_vdag234-B61","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1038\/s41467-023-39119-8","article-title":"Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b","volume":"14","author":"Lenza","year":"2023","journal-title":"Nat Commun"},{"key":"2026093013304848100_vdag234-B62","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/glycob\/cws139","article-title":"The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-\u03b2 secretion from monocytes\/macrophages through the DAP12\u2013Syk pathway","volume":"23","author":"Takamiya","year":"2013","journal-title":"Glycobiology"},{"key":"2026093013304848100_vdag234-B63","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/glycob\/cwm049","article-title":"Siglec-15: an immune system Siglec conserved throughout vertebrate evolution","volume":"17","author":"Angata","year":"2007","journal-title":"Glycobiology"},{"key":"2026093013304848100_vdag234-B64","doi-asserted-by":"publisher","first-page":"1578627","DOI":"10.3389\/fimmu.2025.1578627","article-title":"Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"2026093013304848100_vdag234-B65","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-19-2925","article-title":"Siglec-15 as an emerging target for next-generation cancer immunotherapy","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026093013304848100_vdag234-B66","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/molbev\/mss077","article-title":"Evolution of Siglec-11 and Siglec-16 genes in hominins","volume":"29","author":"Wang","year":"2012","journal-title":"Mol Biol Evol."},{"key":"2026093013304848100_vdag234-B67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12862-017-1075-z","article-title":"Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates","volume":"17","author":"Hayakawa","year":"2017","journal-title":"BMC Evol Biol"},{"key":"2026093013304848100_vdag234-B68","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1523\/JNEUROSCI.3940-09.2010","article-title":"Alleviation of neurotoxicity by microglial human Siglec-11","volume":"30","author":"Wang","year":"2010","journal-title":"J Neurosci"},{"key":"2026093013304848100_vdag234-B69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/glycob\/cwaa082","article-title":"Human-specific microglial Siglec-11 transcript variant has the potential to affect polysialic acid-mediated brain functions at a distance","volume":"31","author":"Hane","year":"2021","journal-title":"Glycobiology"},{"key":"2026093013304848100_vdag234-B70","doi-asserted-by":"publisher","first-page":"1504765","DOI":"10.3389\/fnins.2024.1504765","article-title":"Neuroprotective role of sialic-acid-binding immunoglobulin-like lectin-11 in humanized transgenic mice","volume":"18","author":"Abou Assale","year":"2024","journal-title":"Front Neurosci"},{"key":"2026093013304848100_vdag234-B71","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/eji.200738078","article-title":"SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans","volume":"38","author":"Cao","year":"2008","journal-title":"Eur J Immunol"},{"key":"2026093013304848100_vdag234-B72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010162","article-title":"SIGLEC11 promotes M2 macrophage polarization through AKT\u2013mTOR signaling and facilitates the progression of gastric cancer","volume":"13","author":"Yin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026093013304848100_vdag234-B73","doi-asserted-by":"publisher","first-page":"586820","DOI":"10.3389\/fonc.2020.586820","article-title":"Tumor derived SIGLEC family genes may play roles in tumor genesis, progression, and immune microenvironment regulation","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"2026093013304848100_vdag234-B74","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-22-1488","article-title":"Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients","volume":"29","author":"Thiesler","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026093013304848100_vdag234-B75","doi-asserted-by":"publisher","first-page":"eadf5302","DOI":"10.1126\/scitranslmed.adf5302","article-title":"Targeting the Siglec\u2013sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma","volume":"15","author":"Schmassmann","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026093013304848100_vdag234-B76","doi-asserted-by":"publisher","first-page":"e2107424118","DOI":"10.1073\/pnas.2107424118","article-title":"Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity","volume":"118","author":"Ibarlucea-Benitez","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026093013304848100_vdag234-B77","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14712598.2021.1882989","article-title":"Targeting glyco-immune checkpoints for cancer therapy","volume":"21","author":"Manni","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2026093013304848100_vdag234-B78","doi-asserted-by":"publisher","first-page":"101112","DOI":"10.1016\/j.mam.2022.101112","article-title":"Siglec receptors as new immune checkpoints in cancer","volume":"90","author":"Stanczak","year":"2023","journal-title":"Mol Aspects Med"},{"key":"2026093013304848100_vdag234-B79","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.3390\/ijms23116312","article-title":"Glycan-lectin interactions as novel immunosuppression drivers in glioblastoma","volume":"23","author":"Pace","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026093013304848100_vdag234-B80","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1038\/s41467-023-39683-z","article-title":"Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"issue":":","key":"2026093013304848100_vdag234-B81","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.18632\/oncotarget.12702","article-title":"Targeting immune checkpoints in malignant glioma","volume":"8","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2026093013304848100_vdag234-B82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","article-title":"Sialoglycans and Siglecs can shape the tumor immune microenvironment","volume":"41","author":"van de Wall","year":"2020","journal-title":"Trends Immunol"},{"key":"2026093013304848100_vdag234-B83","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1158\/1078-0432.CCR-14-0820","article-title":"Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier!","volume":"20","author":"Castro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026093013304848100_vdag234-B84","doi-asserted-by":"publisher","author":"Al-Azzawi","year":"2022","DOI":"10.18745\/th.26040"},{"key":"2026093013304848100_vdag234-B85","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fonc.2018.00464","article-title":"Immune checkpoints and innovative therapies in glioblastoma","volume":"8","author":"Romani","year":"2018","journal-title":"Front Oncol"},{"key":"2026093013304848100_vdag234-B86","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.semcancer.2022.02.012","article-title":"Checkpoint: inspecting the barriers in glioblastoma immunotherapies","volume":"86","author":"Preddy","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2026093013304848100_vdag234-B87","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/ijms22041791","article-title":"The paired Siglecs in brain tumours therapy: the immunomodulatory\u00a0effect of dexamethasone and temozolomide in human glioma in vitro model","volume":"22","author":"Wielgat","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026093013304848100_vdag234-B88","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.3390\/ijms21124361","article-title":"Sialic acid-Siglec axis as molecular checkpoints targeting of immune system: smart players in pathology and conventional therapy","volume":"21","author":"Wielgat","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026093013304848100_vdag234-B89","doi-asserted-by":"publisher","first-page":"747690","DOI":"10.3389\/fonc.2021.747690","article-title":"Revisiting the immunological aspects of temozolomide considering the genetic landscape and the immune microenvironment composition of glioblastoma","volume":"11","author":"Di Ianni","year":"2021","journal-title":"Front Oncol"},{"key":"2026093013304848100_vdag234-B90","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12026-019-09106-7","article-title":"The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system","volume":"67","author":"Wielgat","year":"2019","journal-title":"Immunol Res"},{"key":"2026093013304848100_vdag234-B91","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","article-title":"Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline","volume":"35","author":"Sulman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026093013304848100_vdag234-B92","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/107327481702400106","article-title":"Experimental treatments for leptomeningeal metastases from solid malignancies","volume":"24","author":"Sahebjam","year":"2017","journal-title":"Cancer Control"},{"key":"2026093013304848100_vdag234-B93","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"Exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026093013304848100_vdag234-B94","article-title":"A phase 1\/2, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. ClinicalTrials.gov identifier: NCT03665285","volume":"23","author":"NextCure","year":"2018","journal-title":"First Posted October"},{"key":"2026093013304848100_vdag234-B95","author":"NextCure, Inc","year":"2021"},{"key":"2026093013304848100_vdag234-B96","author":"Pyxis Oncology, Inc","year":"2024"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag234\/71000629\/vdag234.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag234\/71000629\/vdag234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag234\/71000629\/vdag234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:30:53Z","timestamp":1790789453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag234\/8788458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag234","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag234"}}